Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Association of ICU Admission Time, Age Stratification, and Clinical Frailty Scale With 30-Day Mortality in Geriatric Oncology Patients

NCT07825090 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-01-01
Last updated
2026-09-17

Condition(s) studied

CancerFrailtyMortality

Investigational drug(s) / intervention(s)

Observation

Observation: Retrospective observational assessment of emergency department boarding time, Clinical Frailty Scale score, age stratification, and their association with 30-day mortality in geriatric oncology patients admitted to the Anesthesiology and Reanimation Intensive Care Unit.

Study summary

Geriatric oncology patients frequently require intensive care admission and are at increased risk of adverse outcomes due to advanced age, frailty, and critical illness. Delays in admission from the emergency department to the intensive care unit (ICU) may further contribute to poor prognosis. This retrospective cohort study aims to evaluate the association of ICU admission time, age stratification, and Clinical Frailty Scale (CFS) score with 30-day mortality among geriatric cancer patients admitted from the emergency department to the Anesthesiology and Reanimation Intensive Care Unit. Secondary objectives include assessing the relationship of these factors with intensive care unit length of stay, hospital length of stay, and in-hospital mortality. The findings may contribute to improved risk stratification and optimization of critical care management in geriatric oncology patients.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 65 years * Diagnosis of solid or hematologic malignancy * Admission from the Emergency Department to the Anesthesiology and Reanimation Intensive Care Unit * ICU admission between January 1, 2026 and July 1, 2026 Exclusion Criteria: * Age \< 65 years * Missing data regarding boarding time, Clinical Frailty Scale score, or 30-day mortality * Readmission to the ICU during the same hospitalization * Patients transferred from hospital wards or other ICUs

Primary outcome measure(s)

  • 30-Day All-Cause Mortality — 30 days
    All cause mortality within 30 days after admission to the Anesthesiology and Reanimation Intensive Care Unit

Trial sites (1)

FacilityCityRegionStatus
Ankara Dr. Abdurrahman Yurtaslan Oncolgy Training and Research Hospital Yenimahalle Ankara
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07825090 on ClinicalTrials.gov ↗ ← All trials in Turkey